WCN26-1935 EFFICACY AND SAFETY OF TELITACICEPT IN TREATMENT OF MINIMAL CHANGE DISEASE AND GENERALIZED MYASTHENIA GRAVIS

Read full text Summarise with VIRAT
Authors: Mengjiao Lin, Yanni Zhou, Liangxiang Xiao
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Minimal Change Disease (MCD) is a major cause of nephrotic syndrome characterized by podocyte injury mediated through immune dysregulation. Myasthenia Gravis (MG) is a rare antibody-mediated autoimmune disease that disrupts neuromuscular transmission, frequently associated with thymic abnormalities. Both conditions represent distinct but overlapping immune pathologies. To describe the clinical course of a patient with refractory MCD complicated by generalized MG, treated successfully with telitacicept.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Myasthenia Gravis and Thymoma Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104300–104300
Publication date
25 March 2026
Language
EN